Jurgen Eberle
Overview
Explore the profile of Jurgen Eberle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542429
Recent advances in melanoma therapy have significantly improved the prognosis of metastasized melanoma. However, large therapeutic gaps remain that need to be closed by new strategies. Antiapoptotic Bcl-2 proteins critically...
3.
Richtig G, Kienzl M, Rittchen S, Roula D, Eberle J, Sarif Z, et al.
Biology (Basel)
. 2023 May;
12(5).
PMID: 37237519
Cannabinoids are mainly used for recreational purposes, but also made their way into oncology, since these substances can be taken to increase appetite in tumour cachexia. Since there are some...
4.
Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902392
Targeting of MAP kinase pathways by BRAF inhibitors has evolved as a key therapy for BRAF-mutated melanoma. However, it cannot be applied for BRAF-WT melanoma, and also, in BRAF-mutated melanoma,...
5.
Hossini A, Hou X, Exner T, Fauler B, Eberle J, Rabien A, et al.
Skin Pharmacol Physiol
. 2022 Nov;
36(1):1-15.
PMID: 36384913
Background: A disruption of sebocyte differentiation and lipogenesis has fatal consequences and can cause a wide spectrum of skin diseases, from acne vulgaris to sebaceous carcinoma, however, the relevant molecular...
6.
Sumarni U, Zhu J, Sinnberg T, Eberle J
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293331
Long-term, curative treatment of cutaneous T-cell lymphomas (CTCL) remains a major challenge. Therapy resistance is often based on apoptosis deficiency, and may depend on antiapoptotic Bcl-2 proteins, such as Bcl-2,...
7.
Schleusener J, Lohan S, Busch L, Ghoreschi K, Lobo Ploch N, May S, et al.
Mycoses
. 2022 Aug;
66(1):25-28.
PMID: 35986595
Fungal infections have increased considerably over the last decades, becoming progressively resistant to common drugs. UVC light has shown microbiological eradication effects, whereby the wavelength of 254 nm is strongly...
8.
Zhu J, Gillissen B, Dang Tran D, May S, Ulrich C, Stockfleth E, et al.
Antioxidants (Basel)
. 2022 Jul;
11(7).
PMID: 35883905
The term sinecatechins designates an extract containing a high percentage of catechins obtained from green tea, which is commercially registered as Veregen or Polyphenon E (PE) and may be considered...
9.
Zhu J, Langer P, Ulrich C, Eberle J
Antioxidants (Basel)
. 2021 Oct;
10(10).
PMID: 34679649
Efficient drugs are needed for countering the worldwide high incidence of cutaneous squamous cell carcinoma (cSCC) and actinic keratosis. Indirubin derivatives represent promising candidates, but their effects in cSCC cells...
10.
Nettelbeck D, Leber M, Altomonte J, Angelova A, Beil J, Berchtold S, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452286
Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction...